To the best of our knowledge, this is the first study to demonstrate the possible effect of Sacubitril/Valsartan, a combination of Ang II receptor blocker and neprilysin inhibitor, on endothelial function and arterial stiffness in HF patients. The gene discussed is MME; the disease is hydrops fetalis.